JHJacob T. Heggestad

Jacob T. Heggestad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jacob T. Heggestad has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Environmentally Resilient Microfluidic Point-of-Care Immunoassay Enables Rapid Diagnosis of Talaromycosis

    by David S. Kinnamon, Jacob T. Heggestad, Jason Liu, Thu Nguyen, Vo Ly, Angus M. Hucknall, Cassio M. Fontes, Rhett J. Britton, Jian-Piao Cai, Jasper Fuk-Woo Chan, et al.

    Point-of-care tests (POCTs) are increasingly being used in field settings, particularly outdoors. The performance of current POCTs─most commonly the lateral flow immunoassay─can be adversely affected by ambient temperature and humidity. We developed a self-contained immunoassay platform─the D4 POCT─that can be conducted at the POC by integrating all reagents in a capillary-driven passive microfluidic cassette that minimizes user intervention. The assay can be imaged and analyzed on a portable fluorescence reader─the D4Scope─and provide quantitative outputs. Here, we systematically investigated the resilience of our D4 POCT to varied temperature and humidity and to physiologically diverse human whole blood samples that span a wide range of physiological hematocrit (30-65%). For all conditions, we showed that the platform maintained high sensitivity (0.05-0.41 ng/mL limits of detection). The platform also demonstrated good accuracy in reporting true analyte concentration across environmental extremes when compared to the manually operated format of the same test to detect a model analyte─ovalbumin. Additionally, we engineered an improved version of the microfluidic cassette that improved the ease-of-use of the device and shortened the time-to-result. We implemented this new cassette to create a rapid diagnostic test to detect talaromycosis infection in patients with advanced HIV disease at the POC, demonstrating comparable sensitivity and specificity to the laboratory test for the disease.


  • COVID-19 Diagnosis and SARS-CoV-2 Strain Identification by a Rapid, Multiplexed, Point-of-Care Antibody Microarray

    by Jacob T. Heggestad, Rhett J. Britton, David S. Kinnamon, Jason Liu, Jack G. Anderson, Daniel Y. Joh, Zachary Quinn, Cassio M. Fontes, Angus M. Hucknall, Robert Parks, et al.

    Antigen tests to detect SARS-CoV-2 have emerged as a promising rapid diagnostic method for COVID-19, but they are unable to differentiate between variants of concern (VOCs). Here, we report a rapid point-of-care test (POC-T), termed CoVariant-SPOT, that uses a set of antibodies that are either tolerant or intolerant to spike protein mutations to identify the likely SARS-CoV-2 strain concurrent with COVID-19 diagnosis using antibodies targeting the nucleocapsid protein. All reagents are incorporated into a portable, multiplexed, and sensitive diagnostic platform built upon a nonfouling polymer brush. To validate CoVariant-SPOT, we tested recombinant SARS-CoV-2 proteins, inactivated viruses, and nasopharyngeal swab samples from COVID-19 positive and negative individuals and showed that CoVariant-SPOT can readily distinguish between two VOCs: Delta and Omicron. We believe that CoVariant-SPOT can serve as a valuable adjunct to next-generation sequencing to rapidly identify variants using a scalable and deployable POC-T, thereby enhancing community surveillance efforts worldwide and informing treatment selection.


  • Open Access

    Rapid test to assess the escape of SARS-CoV-2 variants of concern

    by Jacob T. Heggestad, Rhett J. Britton, David S. Kinnamon, Simone A. Wall, Daniel Y. Joh, Angus M. Hucknall, Lyra B. Olson, Jack G. Anderson, Anna Mazur, Cameron R. Wolfe, et al.

    A rapid test measures neutralizing antibodies against SARS-CoV-2 variants of concern in 1 hour.


  • Smartphone Enabled Point-of-Care Detection of Serum Biomarkers

    by Jacob T. Heggestad, David S. Kinnamon, Jason Liu, Daniel Y. Joh, Cassio M. Fontes, Qingshan Wei, Aydogan Ozcan, Angus M. Hucknall, Ashutosh Chilkoti

    Sandwich immunoassays are the gold standard for detection of protein analytes. Here, we describe an ultrasensitive point-of-care sandwich immunoassay platform for the detection of biomarkers directly from blood or serum using a custom-built smartphone detector. Testing undiluted blood or serum is challenging due to the complexity of the matrix. Proteins nonspecifically adsorb to and cells often adhere to the assay surface, which can drastically impact the analytical sensitivity of the assay. To address this problem, our assay is built upon a “nonfouling” polymer brush “grafted from” a glass slide, which eliminates nearly all nonspecific binding and therefore increases the signal-to-noise ratio and greatly improves the analytical performance of the test. The two components required to perform a sandwich immunoassay are inkjet-printed directly onto the surface: (1) “stable” capture antibodies that remain entrapped in the brush even after exposure to a liquid sample and (2) fluorescently labeled “soluble” detection antibodies that dissolve upon exposure to a liquid sample. The polymer brush provides hydration to the antibodies, allowing them to remain stable and active over prolonged periods of time. When a liquid sample containing a biomarker of interest is dispensed onto the chip, the detection antibodies dissolve and diffuse to the stable capture spots forming a complex that sandwiches the analyte and that has a fluorescence intensity proportional to the concentration of the biomarker in solution, which can be measured using a custom-built smartphone detector. As multiple capture antibodies can be printed as discrete capture spots, the assay can be easily multiplexed without the need for multiple fluorophores. This chip and detector platform can be utilized for the point-of-care detection of low-abundance biomarkers directly from blood or serum in low-resource settings.


  • Open Access

    Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates

    by Daniel Y. Joh, Jacob T. Heggestad, Shengwei Zhang, Gray R. Anderson, Jayanta Bhattacharyya, Suzanne E. Wardell, Simone A. Wall, Amy B. Cheng, Faris Albarghouthi, Jason Liu, et al.


  • Open Access

    Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates

    by Daniel Y. Joh, Jacob T. Heggestad, Shengwei Zhang, Gray R. Anderson, Jayanta Bhattacharyya, Suzanne E. Wardell, Simone A. Wall, Amy B. Cheng, Faris Albarghouthi, Jason Liu, et al.

    Management of breast cancer in limited-resource settings is hindered by a lack of low-cost, logistically sustainable approaches toward molecular and cellular diagnostic pathology services that are needed to guide therapy. To address these limitations, we have developed a multimodal cellphone-based platform—the EpiView-D4—that can evaluate both cellular morphology and molecular expression of clinically relevant biomarkers directly from fine-needle aspiration (FNA) of breast tissue specimens within 1 h. The EpiView-D4 is comprised of two components: (1) an immunodiagnostic chip built upon a “non-fouling” polymer brush-coating (the “D4”) which quantifies expression of protein biomarkers directly from crude cell lysates, and (2) a custom cellphone-based optical microscope (“EpiView”) designed for imaging cytology preparations and D4 assay readout. As a proof-of-concept, we used the EpiView-D4 for assessment of human epidermal growth factor receptor-2 (HER2) expression and validated the performance using cancer cell lines, animal models, and human tissue specimens. We found that FNA cytology specimens (prepared in less than 5 min with rapid staining kits) imaged by the EpiView-D4 were adequate for assessment of lesional cellularity and tumor content. We also found our device could reliably distinguish between HER2 expression levels across multiple different cell lines and animal xenografts. In a pilot study with human tissue (n = 19), we were able to accurately categorize HER2-negative and HER2-positve tumors from FNA specimens. Taken together, the EpiView-D4 offers a promising alternative to invasive—and often unavailable—pathology services and may enable the democratization of effective breast cancer management in limited-resource settings.


  • Open Access

    Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test

    by Jacob T. Heggestad, David S. Kinnamon, Lyra B. Olson, Jason Liu, Garrett Kelly, Simone A. Wall, Solomon Oshabaheebwa, Zachary Quinn, Cassio M. Fontes, Daniel Y. Joh, et al.

    A point-of-care, microfluidic platform detects antibodies against three SARS-CoV-2 antigens from blood in less than an hour.


  • Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR

    by Cassio M. Fontes, Barbara D. Lipes, Jason Liu, Krystle N. Agans, Aiwei Yan, Patricia Shi, Daniela F. Cruz, Garrett Kelly, Kelli M. Luginbuhl, Daniel Y. Joh, et al.

    An immunoassay that targets the nonstructural secreted glycoprotein decoy antigen of Ebola virus detects infection earlier than PCR.